BOULDER, Colo. , March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026, at 1:40 p.m. ET.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to edgewisetx.com or follow us on LinkedIn , X , Facebook and Instagram .
View original content to download multimedia: https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-leerink-global-healthcare-conference-on-march-11-2026-302699637.html
SOURCE Edgewise Therapeutics
/Amazon_com%20Inc_%20storefront%20by-%20%20Markus%20Mainka%20via%20Shutterstock.jpg)
